Acquire Promote as Well as Hold Exactly How Trader Carry Excellent Decission.

Los Angelas, CA -- (SBWIRE) -- 11/12/2012 -- Amarin Corporation plc (NASDAQ:AMRN) is a late-stage biopharmaceutical -company with expertise in lipid science focused on the treatment of cardiovascular disease. The Company’s product candidate is AMR101, an ultra-pure omega-3 fatty acid. It is developing AMR101 for the treatment of patients with high triglyceride levels, or hypertriglyceridemia. In September 2011, it filed a New Drug Application (NDA), with the United States Food and Drug Administration (FDA). Amarin Corporatio (NASDAQ:AMRN) reported EPS of -1.074. For the Current Fiscal year, the company is expected to report EPS of -1.56. For the Next Quarter and Next Year, the company is expected to report EPS of -0.18 and -0.07 respectively. At Current Market Price, AMRN is in distance of -4.65% from its 50-day Moving Average price of $11.7571 and -10.37% from its 200-day Moving Average price of $12.5064. Everyone still has their eyes on Amarin Corporation (NASDAQ: AMRN), which finished the week with a 9.27% rally after Q3 2012 results were reported after Thursday's closing bell. This reaction wiped out almost all of the losses that AMRN shareholders saw between November 5-8.

How Should Investors React to AMRN Now? Find Out Here

The much-anticipated third quarter results provided an update on the company's financial situation, although the real "meat" of the information was found in CEO Joseph Kakrzewski's commentary about the anticipated launch of Vascpea in Q1 2013. Basically, the company is waiting until the second half of this month (November) to hire a sales force for Vascepa. This will guarantee a smooth Vascepa launch in the event that the company doesn't get acquired, or does not get a partner for the pill. Amarin's current CEO, Joseph Zakrzewski, has an ironic twist in his past that gives him key insight into Vascepa's biggest competitor. Since many consider Amarin to be a potential buyout target, Zakrzewski's unique knowledge will give him an edge if options like that come to the table. The biotech space can make or break investors overnight, and when you're talking about Amarin, the success of its new triglyceride-lowering drug is key to the company's future success or failure. The company has huge potential, but don't invest a dollar before reading everything you need to know about Amarin.

Is AMRN Chart Position Shows The Buy Signal: Get Free Analyst Research

The much-anticipated third quarter results provided an update on the company's financial situation, although the real "meat" of the information was found in CEO Joseph Kakrzewski's commentary about the anticipated launch of Vascpea in Q1 2013. Basically, the company is waiting until the second half of this month (November) to hire a sales force for Vascepa. This will guarantee a smooth Vascepa launch in the event that the company doesn't get acquired, or does not get a partner for the pill.

Is AMRN Price will Going Higher: Click Here For Free Alerts

Disclaimer:
Neither HotPennyStockNews.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by HotPennyStockNews.com, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation. HotPennyStockNews.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through HotPennyStockNews.com. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to loose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein..

Contact:
hotpennystocknews.com
info@hotpennystocknews.com